Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study

Table 4 Association between muscle strength and probable liver fibrosis assessed using fibrosis-4 among patients with metabolic dysfunction-associated fatty liver disease

Muscle strength	OR (95%CI)
	Model 1	Model 2	Model 3
1.3 ≤ FIB-4 < 2.67
Q1	2.67 (2.35–3.02)	0.96 (0.82–1.12)	1.03 (0.87–1.21)
Q2–Q4	1 (reference)	1 (reference)	1 (reference)
P value	< 0.001	0.588	0.773
Q1	4.09 (3.50–4.79)	0.89 (0.72–1.09)	1.01 (0.81–1.26)
Q2	2.31 (2.00–2.66)	0.85 (0.71–1.01)	0.94 (0.78–1.13)
Q3	1.67 (1.43–1.94)	0.97 (0.81–1.16)	1.04 (0.86–1.25)
Q4	1 (reference)	1 (reference)	1 (reference)
P for trend	< 0.001	0.117	0.809
FIB-4 ≥ 2.67
Q1	4.71 (3.38–6.56)	1.72 (1.19–2.50)	1.83 (1.25–2.69)
Q2–Q4	1 (reference)	1 (reference)	1 (reference)
P value	< 0.001	0.004	0.002
Q1	8.13 (4.74–13.95)	1.68 (0.89–3.17)	1.85 (0.92–3.74)
Q2	2.25 (1.22–4.15)	0.78 (0.41–1.47)	0.82 (0.41–1.66)
Q3	2.20 (1.18–4.13)	1.26 (0.65–2.46)	1.31 (0.65–2.65)
Q4	1 (reference)	1 (reference)	1 (reference)
P for trend	< 0.001	0.113	0.073

Odds ratios (95% confidence intervals) were calculated using multivariable logistic regression analysis; Model 1 = not adjusted; Model 2 = adjusted for age, sex, income, education, smoking status, and physical activity; Model 3 = Model 2 + alanine aminotransferase, obesity, hypertension, diabetes mellitus, dyslipidemia, and high-sensitivity C-reactive protein. OR: Odds ratio; 95%CI: 95% confidence interval; FIB-4: Fibrosis-4; Q: Quartile.